Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020. 2016-2020 年英格兰成人患者因流感入院的二次医疗资源利用率和相关成本。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-14 DOI: 10.1080/14737167.2024.2427307

Caroline de Courville, Hélène Bricout, Fabián P Alvarez, Jasper Clouting, Sonya Patel, Hafsa Mohamed, Shreena Giblin, Briana Coles

{"title":"Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020.","authors":"Caroline de Courville, Hélène Bricout, Fabián P Alvarez, Jasper Clouting, Sonya Patel, Hafsa Mohamed, Shreena Giblin, Briana Coles","doi":"10.1080/14737167.2024.2427307","DOIUrl":"https://doi.org/10.1080/14737167.2024.2427307","url":null,"abstract":"Introduction: This study aims to investigate healthcare resource utilization and related costs for influenza virus infections in adults admitted into secondary care in England across four influenza seasons.Methods: This study includes all influenza admissions from the Hospital Episode Statistics database (HES) across England, September 2016 to March 2020. Descriptive analyses and comparative modeling techniques were used to assess the impact of influenza on risk groups of interest.Results: Influenza admissions were estimated to cost £401 M. Average admission costs were heavily impacted by age and comorbid status, with comorbid patients representing 91% of costs. Additionally, patients with comorbidities treated in secondary care cost twice as much as non-comorbid patients, after adjusting for age and gender. Comorbid patients also had increased length of stay (LOS) and admissions to ICU, with patients' LOS being a core contributing factor to higher costs.Conclusion: The study documents the substantial burden of influenza in England, emphasizing the impact of age and comorbid status on healthcare resource utilization (HCRU) and related costs. The data presented offers critical information to healthcare systems evaluating new strategies to alleviate the winter pressures on the NHS; highlighting the need to implement vaccination campaigns with enhanced vaccinations and increased vaccine coverage.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell or solid organ transplantation - a perspective of the German healthcare system. 基于全球指南诊断中性粒细胞减少症、造血干细胞或实体器官移植患者粘孢子菌病的成本--德国医疗系统的视角。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-08 DOI: 10.1080/14737167.2024.2426613

Sebastian M Wingen-Heimann, Oliver A Cornely, Danila Seidel, Jon Salmanton-García

{"title":"Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell or solid organ transplantation - a perspective of the German healthcare system.","authors":"Sebastian M Wingen-Heimann, Oliver A Cornely, Danila Seidel, Jon Salmanton-García","doi":"10.1080/14737167.2024.2426613","DOIUrl":"https://doi.org/10.1080/14737167.2024.2426613","url":null,"abstract":"Introduction: Mucormycosis is a rare invasive fungal infection (IFI) which is characterized by prolonged antifungal therapy, high morbidity and mortality rates, as well as increased treatment costs.Areas covered: Appropriate diagnosis of mucormycosis is a fundamental component of successful treatment, however, evidence about health economic expenses does not exist. Based on an international guideline approach for diagnosis of mucormycosis, we calculated costs for imaging-based and laboratory procedures and susceptibility testing from the German statutory health insurance perspective. We therefore analyzed the diagnostic recommendations for patients at increased progression risk, i.e. neutropenia, previous solid organ transplantation or hematopoietic stem cell transplantation.Expert opinion: From the health economic point of view, our analysis underlines the relevance of appropriate guideline-based diagnosis of mucormycosis. The overall costs are relatively low (€499.40 per case) compared to other components in the management of mucormycosis, such as cost-intensive treatment with antifungal agents. Nevertheless, it is important to bear in mind that the level of diagnostic accuracy in line with the global guidelines by the European Confederation of Medical Mycology and the Mycoses Study Group Education and Research Consortium requires substantial resources, which may not be available in all countries or centers, especially in those with low income.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Content and cost of waste pharmaceuticals collected by pharmacies for disposal. 药房收集处置的废弃药品的内容和成本。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-07 DOI: 10.1080/14737167.2024.2424883

Mehmet Akif Erişen, Mesut Ardıç

{"title":"Content and cost of waste pharmaceuticals collected by pharmacies for disposal.","authors":"Mehmet Akif Erişen, Mesut Ardıç","doi":"10.1080/14737167.2024.2424883","DOIUrl":"10.1080/14737167.2024.2424883","url":null,"abstract":"Background: The research aims to the costs and contents of waste pharmaceuticals collected through pharmacies for disposal. This study adds significant value to the country's economy in terms of cost and number of medicines.Methods: The study was conducted with waste pharmaceuticals collected from 29 pharmacies in Erbaa district of Tokat province in Turkey. In the study, the total of waste pharmaceuticals, ATC classification and cost data of these medicines were obtained from the Eczanem automation program. Microsoft Office Excel and IBM SPSS programs were used in the analysis of the data.Results: In the study, 1178 waste pharmaceuticals were evaluated. It was determined that approximately 88% of the waste pharmaceuticals were never used and 30% of them had not expired. Finally, it was determined that the total monthly cost of the collected waste pharmaceuticals was 4,908.88 USD. When this amount is calculated nationwide, the annual estimated cost of waste pharmaceuticals is 58,281,272.36 USD.Conclusion: As a result of the research, it was revealed that waste pharmaceuticals constitute a serious national burden and waste in terms of both number and cost. Therefore, it is important to investigate the causes of waste pharmaceuticals in detail and take measures against them.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142563634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-07 DOI: 10.1080/14737167.2024.2426849

引用次数: 0

Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. 罗拉替尼和克唑替尼一线治疗无性淋巴瘤激酶阳性非小细胞肺癌的成本效益分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-07 DOI: 10.1080/14737167.2024.2421389

YuQi Shang, Hao Guo

{"title":"Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.","authors":"YuQi Shang, Hao Guo","doi":"10.1080/14737167.2024.2421389","DOIUrl":"https://doi.org/10.1080/14737167.2024.2421389","url":null,"abstract":"Objectives: To assess the economic value of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer at medical insurance negotiation prices from the viewpoint of China's health system.Methods: Based on data from the phase III clinical trial, a three-state partitioned survival model was established. In combination with parameters such as treatment costs, utility values, incidence of adverse reactions, and discount rates, the total incremental cost-effectiveness ratio (ICER) was simulated.Results: The results of the fundamental analysis indicated that the patients in the lorlatinib group expended 709,671 yuan more than did the patients in the crizotinib group did but gained 3.09 quality-adjusted life years (QALYs). The ICER value was 229,782.6 yuan/QALY, which was lower than three times the per capita gross domestic product (GDP) of China.Conclusions: Compared with crizotinib, lorlatinib may be a cost-effective first-line treatment choice for advanced ALK-positive NSCLC in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study. 利用 PHAMOUS 研究，将民族健康结果量表 (HoNOS) 和积极与消极症状量表 (PANSS) 与精神病患者的 EQ-5D-3L 进行映射。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-06 DOI: 10.1080/14737167.2024.2422456

Anne Kleijburg, Ben Wijnen, Wouter den Hollander, Silvia Evers, Hans Kroon, Joran Lokkerbol

{"title":"Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study.","authors":"Anne Kleijburg, Ben Wijnen, Wouter den Hollander, Silvia Evers, Hans Kroon, Joran Lokkerbol","doi":"10.1080/14737167.2024.2422456","DOIUrl":"10.1080/14737167.2024.2422456","url":null,"abstract":"Objectives: When health outcomes relevant for economic evaluations are unavailable, algorithms can be developed to map utilities using available clinical outcome measures. This study aims to develop two mapping algorithms estimating EuroQol-5 dimension-3 level (EQ-5D-3 L) utilities using the clinician-rated Health of the Nation Outcome Scores (HoNOS) and Positive and Negative Syndrome Scale (PANNS).Methods: A dataset with 2,029 observations of patients with psychotic disorders included EQ-5D-3 L, HoNOS, PANSS item scores, and demographics. Correlations between instruments were evaluated. Least Absolute Shrinkage and Selection Operator (LASSO) regression and random forest (RF) algorithms with various predictor variable sets were applied. Model performance was cross-validated using R-squared and Root Mean Square Error (RMSE).Results: High ceiling effects were observed for EQ-5D-3 L, with weak to moderate negative correlations between EQ-5D and HoNOS (r = -0.34) and PANSS (r = -0.27). Overall, LASSO models outperformed RF models, with individual item models performing best for the HoNOS and PANSS, with the best observed RMSEs of 0.241 and 0.231, respectively.Conclusions: The HoNOS and PANSS could be mapped onto EQ-5D-3 L utilities but lack accuracy for individual patient predictions. However, in the absence of alternatives, they could adequately predict population-based utility score differences for health economic evaluations.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc). 阿特珠单抗联合贝伐单抗和化疗治疗转移性、顽固性或复发性宫颈癌（BEATcc）的成本效益分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-04 DOI: 10.1080/14737167.2024.2422465

Yixiao Zhu, Fenghao Shi, Huiting Lin, Yingdan Cao, Hongbin Yi, Sheng Han, Xiaoxia Wei

{"title":"Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc).","authors":"Yixiao Zhu, Fenghao Shi, Huiting Lin, Yingdan Cao, Hongbin Yi, Sheng Han, Xiaoxia Wei","doi":"10.1080/14737167.2024.2422465","DOIUrl":"10.1080/14737167.2024.2422465","url":null,"abstract":"Background: The addition of atezolizumab to bevacizumab plus platinum regimen has demonstrated notable improvements in treating metastatic, persistent, or recurrent cervical cancer, but its cost-effectiveness requires further investigation. From a US payer perspective, we aimed to evaluate the cost-effectiveness of atezolizumab plus bevacizumab and chemotherapy vs. standard chemotherapy as a first-line treatment for metastatic, persistent, or recurrent cervical cancer.Methods: A partitioned survival model based on the data from the BEATcc trial was used to calculate the incremental cost-effectiveness ratio (ICER), using cost and health utility information obtained from literature and publicly accessible databases. One-way and probabilistic sensitivity analyses were performed to evaluate the model's responsiveness to variations in parameters.Results: The addition of atezolizumab resulted in an additional 0.839 quality-adjusted life years (QALY) at an additional cost of $458,237, leading to an ICER of $545,943/QALY. One-way sensitivity analysis indicated that the cost of atezolizumab had the greatest impact on the ICER, followed by the utility value of progression-free survival (PFS) and follow-up costs. Probabilistic sensitivity analysis showed a 0% cost-effectiveness probability at the current willingness-to-pay (WTP) threshold of $150,000 per QALY.Conclusion: Adding atezolizumab to chemotherapy is cost-prohibitive in the US and may not be cost-effective for patients.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-04 DOI: 10.1080/14737167.2024.2424062

引用次数: 0

Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies. 中低收入国家自杀和自杀未遂的经济负担：成本计算研究的系统回顾。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI: 10.1080/14737167.2024.2388132

Nikhil Jain, Ben Wijnen, Isha Lohumi, Susmita Chatterjee, Silvia M A A Evers

{"title":"Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies.","authors":"Nikhil Jain, Ben Wijnen, Isha Lohumi, Susmita Chatterjee, Silvia M A A Evers","doi":"10.1080/14737167.2024.2388132","DOIUrl":"10.1080/14737167.2024.2388132","url":null,"abstract":"Introduction: Suicide is a major public health concern in low- and middle-income countries (LMICs) due to its substantial psychological, social, and economic impact. There is little synthesized evidence to estimate the economic burden of suicide and suicide attempts in such economies. The present systematic literature review aims to examine existing evidence on the cost of illness (COI) in the case of suicides and suicide attempts and assess their quality.Methods: A systematic review was carried out using electronic databases, such as Medline, EMBASE, EconLit, PsycINFO, and CINAHL using keywords like 'suicide and suicide attempts,' 'cost of illness,' and economic burden.\" The quality assessment of studies was conducted along with the per-person cost estimation to understand the variation of methods followed across the studies.Result: 14 studies qualified for final data extraction and synthesis out of 4,164 studies. The studies showed heterogeneity across objectives, settings, and methods, with cost estimates reflecting a wide range of costings per person in suicide and suicide attempts.Conclusion: It is challenging to determine and compare the economic estimates of suicide. Intensive research is warranted with standardized cost assessment techniques and wider perspectives to understand the true economic burden of suicide.Registration: PROSPERO Registration No- CRD42022294080.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. 我国大面积小细胞肺癌癌症一线化疗加用塞普利单抗的成本效益。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-11-01 Epub Date: 2023-11-10 DOI: 10.1080/14737167.2023.2281606

Shuo Kang, Huanlong Liu

{"title":"Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.","authors":"Shuo Kang, Huanlong Liu","doi":"10.1080/14737167.2023.2281606","DOIUrl":"10.1080/14737167.2023.2281606","url":null,"abstract":"Objective: The aim of the current study was to evaluate the cost-effectiveness of serplulimab plus chemotherapy compared chemotherapy alone as first-line strategy for patients with ES-SCLC in China.Methods: A decision-analytic model that based on the Chinese health-care system perspective was conducted to evaluate the economic benefits for the two competing first-line treatment. The clinical survival and safety data were obtained from the ASTRUM-005 trial, cost and utility values were gathered from the local charges and previously published study. Both cost and utility values were discounted at an annual rate of 5%. Sensitivity analyses and subgroup analyses were performed to examine the robustness of the model results.Results: Serplulimab plus chemotherapy could bring additional 0.25 QALYs with the marginal cost of $37,569.32, resulting in an ICER of $147,908.74 per additional QALY gained. Sensitivity analyses confirmed that model results were robust. Subgroup analyses revealed that adding serplulimab to first-line chemotherapy were unlikely to be the cost-effective option for all subgroup patients.Conclusions: Serplulimab plus chemotherapy was unlikely to be the cost-effective first-line strategy compared with chemotherapy alone for patients with ES-SCLC in China. Reduced the price of serplulimab could increase its cost-effective.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0